HOLLISTON, Mass., Oct. 18, 2017 -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its third quarter 2017 after market trading hours on Thursday, October 26, 2017. A conference call to discuss the company's third quarter 2017 financial results and its operations is scheduled for that same date at 4:30 PM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer; and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-800-708-4539, or international: 1-847-619-6396, and referencing the conference ID# 45846204.
The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at:
http://investor.harvardbioscience.com/
and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.
If you are unable to listen to the live conference call, the webcast will be available on the Company's website through November 2, 2017.
To add this meeting to your calendar visit: http://investor.harvardbioscience.com/ and click “remind me”.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
CONTACT: Corey Manchester Director, Finance and Investor Relations Tel: 508 893 8999


Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 



